-
-
-
-
-
-
-
Zealand Pharma Announces Financial Results for the First Nine Months of 2023
-
-
-
-
-
-
-
Zealand Pharma announces acceleration of U.S. commercial operations through the completion of the Valeritas acquisition; FDA acceptance of New Drug Application submission for the dasiglucagon HypoPal�
-
-
-
-
-
-
-
Zealand announces new timelines for a U.S. FDA decision on iGlarLixi, the fixed-ratio combination of lixisenatide (AdlyxinTM) and Lantus(r), for the treatment of type 2 diabetes
15,690 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

